Increased systemic sST2 in patients with end stage renal disease contributes to milder liver damage during HCV infection | Zendy

Ružica Lukić | Zendy; Maja Ćupić | Zendy; Nevena Gajović | Zendy; Milena Jurišević | Zendy; Željko Mijailović | Zendy; Bojana Davidović | Zendy; Bojan Kujundžić | Zendy; Bojan Joksimović | Zendy; Nebojša Arsenijević | Zendy; Ivan Jovanović | Zendy

Open Access

Increased systemic sST2 in patients with end stage renal disease contributes to milder liver damage during HCV infection

Author(s) -

Ružica Lukić,

Maja Ćupić,

Nevena Gajović,

Milena Jurišević,

Željko Mijailović,

Bojana Davidović,

Bojan Kujundžić,

Bojan Joksimović,

Nebojša Arsenijević,

Ivan Jovanović

Publication year - 2020

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.11741

Subject(s) - end stage renal disease , medicine , liver disease , gastroenterology , stage (stratigraphy) , disease , liver damage , immunology , biology , paleontology

Hepatitis C Virus (HCV) is the leading cause of chronic liver disease and is a serious global health problem. Hepatitis C infection is highly prevalent in patients with end stage renal disease (ESRD), due to frequent exposure to blood and blood products, nosocomial transmission of HCV, and prolong hemodialysis duration. The aim of the study was to evaluate the influence of IL-33/ST2 signaling pathway on severity of the liver disease in ESRD HCV+ patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research